PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
NCT ID: NCT04272658
Last Updated: 2024-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
56 participants
OBSERVATIONAL
2020-06-26
2026-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
NCT03741231
Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients
NCT03353090
MPDL3280A-imaging-IST-UMCG
NCT02453984
PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma
NCT00828126
Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
NCT01573494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
value of 4D body-to-whole dynamic acquisition in FDG
differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this "unconfirmed progression" after 2 new treatment cures of immune checkpoint inhibitors in metastatic melanoma
value of 4D body-to-whole dynamic acquisition in FDG
differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this "unconfirmed progression" after 2 new treatment cures of ICI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
value of 4D body-to-whole dynamic acquisition in FDG
differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this "unconfirmed progression" after 2 new treatment cures of ICI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With metastatic melanoma
* Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
* Having formulated a non-opposition
Exclusion Criteria
* Pregnancy or breastfeeding
* Other type of tumor than metastatic melanoma
* Non-eligibility for the examination
* Refusal of participation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronan ABGRAL, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
Nuclear Medecine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital University ff Brest
Brest, Finistere, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ronan ABGRAL, MD-PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29BRC19.0194 (IMMUNO-PET2)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.